TRAQinform IQ vs PeraMobile and PeraWatch

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

TRAQinform IQ

by AIQ Global

PeraMobile and PeraWatch

by PeraHealth (acquired by Spacelabs Healthcare)

AI Verdict

TRAQinform IQ specializes in quantitative analysis of lesions from PET/CT scans for oncology and nuclear medicine, focusing on treatment response and disease progression. PeraMobile and PeraWatch, conversely, provide predictive analytics and real-time patient acuity scoring to identify at-risk patients across general hospital populations. While both offer clinical decision support and patient monitoring, their core functionalities, data sources, and target clinical problems are distinct.

Choose TRAQinform IQ if…

Choose TRAQinform IQ if your primary need is precise, quantitative analysis of lesions from PET/CT scans to accurately monitor disease progression and treatment response in oncology or nuclear medicine. This tool is ideal for clinicians who require automated segmentation, matching, and objective measurement of changes in lesion volume and tracer uptake over time.

View TRAQinform IQ →

Choose PeraMobile and PeraWatch if…

Choose PeraMobile and PeraWatch if your organization requires a comprehensive, real-time predictive analytics solution to identify at-risk patients across your entire healthcare system. This is best suited for care teams needing proactive alerts for patient deterioration, mobile access to acuity scores, and seamless integration with existing EHRs to enable earlier intervention and improve overall patient outcomes.

View PeraMobile and PeraWatch →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	TRAQinform IQ	PeraMobile and PeraWatch
Pricing	Unknown	Contact for pricing
Deployment	SaaS; cloud-based; on prem; hybrid; web browser access	Software-only, integrated with EHRs, web-based access, mobile application, on user-provided hardware.
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

PeraMobile and PeraWatch

PeraMobile and PeraWatch explicitly highlight a mobile application and visual dashboards for patient condition trends, suggesting a strong focus on intuitive access and real-time insights for clinicians on the go. While TRAQinform IQ offers web browser access and detailed reports, it does not emphasize the same level of mobile-first design or visual dashboarding for immediate clinical action.

Clinical Value

Tie

Both tools offer significant and FDA-cleared clinical value in distinct areas. TRAQinform IQ provides crucial quantitative analysis for oncology treatment response, aiding in disease progression monitoring. PeraMobile and PeraWatch offer real-time predictive analytics to identify at-risk patients for earlier intervention, improving patient safety and outcomes.

Pricing & Value

Tie

Neither TRAQinform IQ nor PeraMobile/PeraWatch provide publicly disclosed pricing information, both requiring direct contact for quotes. Without any cost details, it is impossible to conduct a head-to-head comparison of their value propositions or overall pricing.

Enterprise Readiness

TRAQinform IQ

TRAQinform IQ explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA) in place, providing clear documentation for enterprise-level compliance. While PeraMobile and PeraWatch state these are 'Likely,' the explicit confirmation from TRAQinform IQ offers a stronger assurance for organizations prioritizing formal compliance documentation. Both offer flexible deployment options and interoperability.

Innovation

TRAQinform IQ

TRAQinform IQ's key features, such as 'Automated anatomical and skeletal segmentation' and 'Automated matching and quantitative assessment of ROIs between multiple PET/CT scans,' demonstrate advanced AI application in complex medical imaging analysis. While PeraMobile and PeraWatch offer valuable predictive analytics based on the Rothman Index, TRAQinform IQ's specific image processing capabilities appear to push the boundaries of AI in a more novel way within its domain.

Support & Docs

PeraMobile and PeraWatch

PeraHealth, the company behind PeraMobile and PeraWatch, is now part of Spacelabs Healthcare, a larger and more established medical technology company. This acquisition suggests that PeraMobile and PeraWatch likely benefit from a more robust and structured support system and comprehensive documentation inherent to a larger corporate entity, compared to AIQ Global for TRAQinform IQ, for which specific support details are not readily available.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	TRAQinform IQ	PeraMobile and PeraWatch
Tool Name	TRAQinform IQ	PeraMobile and PeraWatch
Company	AIQ Global	PeraHealth (acquired by Spacelabs Healthcare)
Primary Focus	Quantitative analysis of lesions in PET/CT scans, aiding clinicians in monitoring disease progression and treatment response in oncology and nuclear medicine.	Predictive analytics solutions to help healthcare providers identify at-risk patients sooner for earlier intervention, improve quality, and reduce costs.
Key Analytical Function	Automated matching and quantitative assessment of ROIs between multiple PET/CT scans; Generates detailed reports on lesion volume and tracer uptake changes.	Real-time patient acuity scoring (Rothman Index); Predictive analytics for patient deterioration.
Access & Surveillance	Clinical decision support, Patient monitoring, Medical imaging.	Mobile access for on-the-go clinicians (PeraMobile), System-wide virtual surveillance (PeraWatch), Visual dashboards of patient condition trends (PeraTrend).

Videos

Demos, reviews, and walkthroughs featuring TRAQinform IQ and PeraMobile and PeraWatch.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of each tool?

TRAQinform IQ is designed for quantitative analysis of lesions in PET/CT scans, aiding clinicians in oncology and nuclear medicine to monitor disease progression and treatment response. PeraMobile and PeraWatch offer predictive analytics to help healthcare providers identify at-risk patients sooner for earlier intervention, improve quality, and reduce costs.

How do these tools leverage AI or specific algorithms?

TRAQinform IQ is an AI software tool that utilizes machine learning for automated anatomical and skeletal segmentation and quantitative assessment of regions of interest (ROIs) in PET/CT scans. PeraMobile and PeraWatch are powered by the FDA-cleared Rothman Index, which provides real-time patient acuity scoring and predictive analytics for patient deterioration.

What types of data do these tools primarily analyze?

TRAQinform IQ primarily analyzes quantitative data from lesions in PET/CT scans, including lesion volume and tracer uptake changes. PeraMobile and PeraWatch integrate with Electronic Health Records (EHRs) to assimilate disparate clinical data for patient acuity scoring and predictive analytics.

How do the reporting and output features differ?

TRAQinform IQ generates detailed reports on lesion volume and tracer uptake changes, providing quantitative analysis of lesions. PeraMobile and PeraWatch offer real-time patient acuity scoring, visual dashboards of patient condition trends (PeraTrend), configurable warning states, and push notifications.

How do these tools integrate with existing clinical workflows or systems?

TRAQinform IQ mentions interoperability and is designed to integrate seamlessly into existing clinical workflows. PeraMobile and PeraWatch explicitly integrate with major EHR vendors and offer mobile access for on-the-go clinicians.